$0.54
3.65% day before yesterday
Nasdaq, Sep 06, 10:18 pm CET
ISIN
US04746L1044
Symbol
ATHA
Sector
Industry

Athira Pharma Inc Stock price

$0.54
-2.61 82.81% 1M
-3.36 86.12% 6M
-1.89 77.72% YTD
-1.68 75.61% 1Y
-10.12 94.92% 3Y
-16.46 96.82% 5Y
-16.46 96.82% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.02 3.65%
ISIN
US04746L1044
Symbol
ATHA
Sector
Industry

Key metrics

Market capitalization $20.81m
Enterprise Value $-77.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.79
P/B ratio (TTM) P/B ratio 0.25
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-121.40m
Free Cash Flow (TTM) Free Cash Flow $-98.47m
Cash position $100.14m
EPS (TTM) EPS $-2.97
P/E forward negative
Short interest 3.66%
Show more

Is Athira Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Athira Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Athira Pharma Inc forecast:

1x Buy
17%
5x Hold
83%

Analyst Opinions

6 Analysts have issued a Athira Pharma Inc forecast:

Buy
17%
Hold
83%

Financial data from Athira Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.97 0.97
17% 17%
-
-0.97 -0.97
17% 17%
-
- Selling and Administrative Expenses 26 26
18% 18%
-
- Research and Development Expense 93 93
26% 26%
-
-120 -120
12% 12%
-
- Depreciation and Amortization 0.97 0.97
17% 17%
-
EBIT (Operating Income) EBIT -121 -121
12% 12%
-
Net Profit -113 -113
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Athira Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Athira Pharma Inc Stock News

Negative
Reuters
4 days ago
Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.
Neutral
GlobeNewsWire
4 days ago
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23)
Neutral
GlobeNewsWire
about one month ago
Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 202...
More Athira Pharma Inc News

Company Profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.

Head office United States
CEO Mark Litton
Employees 67
Founded 2011
Website www.athira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today